Skip to content

ZTS

Zoetis Inc.

NYSE · USHealthcareDrug Manufacturers - Specialty & Generic
$76.19-0.48%

Price as of Jul 20, 2026

ZTS growth

Zoetis Inc. growth

Reported trailing growth, forward expectations and three-year compound growth rates.

Trailing growth

Year over year

Revenue
+2.4%
EBITDA
+2.7%
EBIT
+4.0%
EPS
+8.2%
Free cash flow
-6.4%
Operating cash flow
-7.7%

Forward estimates

Revenue
+6.4%
EBITDA
+13.5%
EPS
+19.6%

Three-year CAGR

Revenue
+5.4%
EBITDA
+6.6%
EBIT
+7.1%
Net income
+8.1%
EPS
+10.2%
Free cash flow
+19.9%

Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.